Search

Home > New FDA Approvals > 102 - Latuda for BPD in pediatric patients; FDA statement on Essure; First test to screen for tickborne parasites
Podcast: New FDA Approvals
Episode:

102 - Latuda for BPD in pediatric patients; FDA statement on Essure; First test to screen for tickborne parasites
Category: Science & Medicine
Duration: 00:09:05
Publish Date: 2018-03-08 07:00:00
Description:

March 8, 2018 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com

1:25 Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda® (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age) http://www.pharmalive.com/fda-grants-sunovions-latuda-expanded-approval-for-bipolar-depression-in-pediatric-patients/

3:44 Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA activities related to the ongoing post-market review of Essure and FDA’s commitment to keep women informed https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm600052.htm

5:40 FDA approves first tests to screen for tickborne parasite in whole blood and plasma to protect the U.S. blood supply https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm599782.htm

7:50 6weekcourse.com The 6-week course covers everything you need to know to start your freelance medical writing business. The course is directed towards people with writing ability, English fluency, and a PhD, MD, or other advanced degree in a science.

The next 6-Week Course will begin on Monday April 9th, 2018. Registration for the course will begin on Monday April 2nd, at noon EDT and will close on Saturday April 7th at noon EDT. Please log on to learn.6weekcourse.com to register.

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/
Total Play: 0